Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Firategrast
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
Secondary Progressive Multiple Sclerosis: Definition and Measurement.
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.
Breastfeeding and multiple sclerosis relapses: a meta-analysis.
Predictors of Fatigue Impact in Persons With Long-Standing Multiple Sclerosis.
Dimethyl fumarate for multiple sclerosis.
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Sex hormones and multiple sclerosis: another informative failure.
Multiple sclerosis prevalence in the United States commercially insured population.
Pharmacokinetics and metabolism of mitoxantrone. A review.
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Randomized study combining interferon & glatiramer acetate in multiple sclerosis.
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

Pages